Platelets >= 75,000/uL unless related to bone marrow involvement by HIV-cHL
Platelet count >= 50,000/uL (unless documented bone marrow involvement with lymphoma)
Subjects with a bone marrow biopsy which shows microscopic, low-level involvement of lymphoma are eligible
NOTE: these requirements do not apply to those with marrow involvement of lymphoma (any extent)
Platelet count >= 75,000/?L (unless documented bone marrow involvement with lymphoma)
Patients must have histologically or cytologically confirmed non-Hodgkin’s lymphoma for which standard therapies do not exist or are no longer effective; to be eligible for this study, lymphoma patients must have no marrow involvement as documented by routine marrow aspiration and biopsy performed within 30 days of study entry
Platelets >= 100,000, unless due to direct bone marrow involvement of disease
Platelets >= 75,000/mcL (>= 30,000 if there is bone marrow involvement with lymphoma)
Platelets >= 50,000/mm^3\r\n* Exception: unless documented bone marrow involvement by lymphoma
Platelets >= 75,000/mcL, unless due to marrow involvement by lymphoma in which case a platelet count of >= 30,000/mcL will be used
Absolute neutrophil count >= 1000/mm^3 within 45 days prior to initiation of therapy. (Patients with documented marrow involvement (with lymphoma) or hypersplenism secondary to involvement of the spleen by lymphoma at the time of randomization are not required to meet the parameter).
Platelet count >= 75K /mm^3 within 45 days prior to initiation of therapy. (Patients with documented marrow involvement (with lymphoma) or hypersplenism secondary to involvement of the spleen by lymphoma at the time of randomization are not required to meet the parameter).
Serum creatinine =< 2.0 mg/dL or creatinine clearance of > 40 ml/min within 45 days prior to initiation of therapy. (Patients with documented marrow involvement (with lymphoma) or hypersplenism secondary to involvement of the spleen by lymphoma at the time of randomization are not required to meet the parameter).
Total bilirubin =< 1.5 mg/dL within 45 days prior to initiation of therapy. (Patients with documented marrow involvement (with lymphoma) or hypersplenism secondary to involvement of the spleen by lymphoma at the time of randomization are not required to meet the parameter).
Patients with blood or platelet transfusion within 1 week prior to signing Consent A, or with platelets < 50,000/mm^3, neutrophils < 750/mm^3, or hemoglobin < 8.5 g/dL, unless the cytopenias are considered by the treating physician to be largely due to marrow involvement by lymphoma
Platelets >= 75,000/mcL (unless dysfunction is secondary to lymphoma involvement)
Patients must have measurable malignancy as defined by at least one of the criteria below\r\n* Lymphoma mass that is measurable (minimum 1.5 cm in largest diameter) by computed tomography (CT) scan is required unless bone marrow lymphoma is detectable\r\n* For a lymphoma mass to count as measurable malignancy, it must have abnormally increased metabolic activity when assessed by positron emission tomography (PET) scan\r\n* For lymphoma with only bone marrow involvement, no mass is necessary, but if a mass is not present, bone marrow malignancy must be detectable by flow cytometry
Platelets: >= 75,000/mm^3, unless decreased due to bone marrow involvement with lymphoma
Platelet >= 75,000/mm^3\r\n*Unless related to bone marrow involvement with disease, in which case platelets must be >= 50,000/mm^3
Parenchymal brain involvement with lymphoma
Platelet count >= 75,000/ul (unless documented bone marrow involvement with lymphoma)
Platelets > 100,000/mm^3 unless deemed related to lymphoma involvement in the bone marrow and felt potentially reversible by the treating physician
Platelets >= 100,000/mcL except in cases of marrow infiltration by lymphoma
Platelet count >= 50 x 10^9/L (>= 20 x 10^9/L if lymphoma involvement in the pre-treatment bone marrow is found) within 14 days prior to starting therapy
Platelets > 75,000, unless due to direct bone marrow involvement of disease
To be performed within 14 days prior to day 1 of protocol therapy: platelets >= 30,000/mm^3\r\n* NOTE: Platelet transfusions are not permitted within 7 days of platelet assessment unless cytopenia is secondary to disease involvement\r\n* Exception: Unless documented bone marrow involvement by lymphoma
Platelets > 75,000, unless due to direct bone marrow involvement of disease
Platelets >= 70,000/mcL, OR >= 50,000/mcL if lymphomatous bone marrow involvement; patients with documented marrow involvement may be transfused to this value, performed within 10 days of treatment initiation
Platelets >= 75,000 / mcL if no bone marrow involvement, platelets >= 50,000 / mcL if documented bone marrow involvement
Platelets >= 75,000/mm^3 (unless these parameters are abnormal secondary to lymphomatous involvement of bone marrow); all participants must cease colony-stimulating factor therapy at least 24 hours prior to institution of cycle 1 chemotherapy
Part 1: platelets >= 75,000/mcl; Part 2: platelets >= 50,000/mcl if there is bone marrow involvement by lymphoma; platelets >= 75,000/mcl if there is no bone marrow involvement
Platelets >= 100,000/mm^3 (100 x 10^9/L) (unless due to marrow involvement) obtained within 4 weeks prior to registration
Platelets >= 100,000/mcl unless in the opinion of the treating physician, thrombocytopenia is due to splenomegaly or bone marrow involvement
If bone marrow is involved with lymphoma and normal marrow function prior to onset of lymphoma is documented: ANC of > 750
If bone marrow is involved with lymphoma and normal marrow function prior to onset of lymphoma is documented: any hemoglobin
If bone marrow is involved with lymphoma and normal marrow function prior to onset of lymphoma is documented: platelets of > 50,000/mm^3
Platelets >= 100,000/ul (unless these abnormalities are due to bone marrow involvement)
Platelets >= 75,000 total (>= 50,000 if bone marrow involvement)
Platelets >= 75,000/uL (unless significant bone marrow involvement with MCL)
Patients with documented marrow involvement by lymphoma at the time of registration are not required to meet the above hematologic parameters
Platelets >= 50,000/uL (unless documented bone marrow involvement with lymphoma)
Platelets > 75,000 unless impairment due to organ involvement by lymphoma
Lymphoma participants without bone marrow involvement must have platelet count >= 50,000/mm^3 (without transfusion support); Note: these criteria are waived for participants with leukemia or lymphoma participants with bone marrow involvement
Platelets >= 75,000 unless cytopenias are related to bone marrow involvement with disease
Have evidence of bone marrow involvement of lymphoma at time of transplant staging
Platelets >= 100 x 10^9/L without platelet transfusion dependency, unless due to bone marrow involvement with lymphoma
Platelets >= 75,000/mcL (unless due to lymphoma involvement of the bone marrow)
Platelets >= 75,000/uL, unless due to bone marrow involvement by lymphoma
platelets ?30,000/?L in absence of bone marrow involvement
Platelets ?100,000/µL (unless due to documented leukemic involvement of the bone marrow at the time of study entry).
Screening laboratory values: Neutrophils < 1.5 x 109/L (unless due to NHL involvement of the bone marrow). Platelets < 100 x 109/L (unless due to NHL involvement of the bone marrow). Serum creatinine ?2.0 mg/dL; subjects with serum creatinine ?2.0 mg/dL are eligible if the creatinine clearance (Cockcroft Gault equation [Cockcroft, 1976]) is ?40 mL/min. Total bilirubin > 1.5 times ULN [upper normal limit] (unless due to liver involvement by NHL or Gilbert's disease). Transaminases > 3 times ULN (unless due to NHL involvement).
Neutrophils < 1.5 x 10^9/L (unless due to iNHL involvement of the bone marrow)
Platelets < 50 x 10^9/L (unless due to iNHL involvement of the bone marrow)
Adequate hematologic function (unless abnormalities related to lymphoma infiltration of the bone marrow or hypersplenism due to lymphoma) as follows:
Platelets > 100,000/mm^3 unless deemed likely related to lymphoma involvement in the bone marrow where minimum allowable platelet count will be 50,000/mm^3
Platelets >= 75,000/?L unless due to marrow involvement by lymphoma
Hemoglobin > 7.0 g/dL unless due to marrow involvement by lymphoma
Platelets >= 100 x 10^9/L (or platelet count >= 30 x 10^9 cells/L in patients with lymphoma or CLL if bone marrow disease involvement is documented)
